Arizona Builders Alliance hires Tricia Schmidt

Arizona Builders Alliance hires Tricia Schmidt as Director of Apprenticeship. In this new role, she will be responsible for program design, outreach and compliance for the ABA. In addition, Schmidt is looking towards incorporating synergy and structure which will in-turn elevate program awareness, funding, participation, retention and diversity. 

Schmidt brings over 30 years of experience in commercial aviation where she was responsible for curriculum development, instruction, and the integration of policies and procedures. At the height of her aviation career, she was cabin safety manager where she supported the safety reporting system in its evolution from paper to online and enacted the Aviation Safety Action Program

“Tricia has invaluable experience leading teams, improving instructor outcomes and is a great addition to the ABA,” said Tom Dunn, ABA President. “In these changing times, we will all be working towards expanding our apprenticeship program and offering more ways to learn about the great opportunities in construction.” 

After retiring from the aviation industry, Schmidt obtained her certification in Human Resources, SHRM-CP, leading her to her most recent position as the training coordinator for TDIndustries, Inc. Schmidt demonstrated excellence in managing leadership and development training, recruiting top industry professionals for mechanical construction, and further developing the apprenticeship program for the following crafts: pipefitting, plumbing, sheet metal, and HVAC trades. 

“I am looking forward to building a strong ABA apprenticeship team and partnering with our community and industry employers as we promote opportunities that result in rewarding careers,” remarked Schmidt. “The need for skilled trades is endless and collaboration is essential to fill this gap.” 

MacQueen & Gottlieb promotes Pam Molnar

MacQueen & Gottlieb, Arizona’s top-ranked real estate law firm, today announced the promotion of Pam Molnar from Financial Analyst to Director of Administration. In her new position, Molnar will have a greater hand in the day-to-day operation of the firm. Founding partner Benjamin Gottlieb praised Molnar’s skill and dedication.

“As part of our firm’s commitment to growth and professional development, Pam Molnar has been promoted from Financial Analyst to Director of Administration,” Gottlieb said. “Her promotion reflects the fact that she has come in and made a tremendous impact on our firm very quickly. In less than a year she grew out of the position she initially was hired for and it became apparent we were going to have to find her a more substantive role.”

Her new role will match Molnar’s diverse skill set with the needs of the growing firm. Molnar holds the prestigious Certified Legal Manager (CLM) certification from the Association of Legal Administrators (ALA), where she is a past president.  This hard-to-achieve designation signifies that Pam has demonstrated a mastery of five core areas identified by the industry as effective law firm management: human resources; communications and organization; finance; operations; and legal industry/business management.  Currently, Pam serves on the ALA board of directors as their newsletter chairperson and will assume the role of Secretary in April. With MacQueen & Gottlieb growing rapidly, now at 14 people, that growth will require Molnar to employ a wide variety of her skills including streamlining procedures, implement time management strategies and creating more efficient systems to manage that growth. Some of the specific areas she will be involved with include human resources; facilities; finance and accounting; personnel; information management; library and research services; and community and client services.

On the Money welcomes Rick Hornung

On the Money, LLC, an accounting and bookkeeping firm in Phoenix, welcomes finance professional Rick Hornung, a successful chief financial officer and skilled controller who brings 22 years of experience in finance, accounting and human resources. 

Rick recently converted accounting systems for a national petroleum company and has worked as a controller for a multi-branch retailer and a national nonprofit organization. His expertise is well-suited for tackling technical accounting and finance projects for medium to large corporations. Yet he is also well-versed in providing financial consulting and accounting services to small and medium-sized private companies and nonprofits.

“We’re very excited to have Rick join our team,” said Ruth Urban, On the Money’s president and CEO. “The breadth of accounting and finance experience he brings from both the public and private sectors makes him a valuable member of our team.”

Rick holds a bachelor’s degree in economics from the University of Washington in Seattle, where he previously lived and worked as a licensed CPA.

C-Path appoints Dr. Klaus Romero as chief science officer

The Critical Path Institute (C-Path) announced the appointment of Klaus Romero, M.D., M.S., F.C.P., as its new Chief Science Officer (CSO) effective April 1, 2020. Dr. Romero, a clinical pharmacologist and epidemiologist with more than 17 years combined experience in academic and pharmaceutical clinical research, translational sciences, pharmacometrics, modeling and simulation and pharmacoepidemiology, has been with C-Path since December 2007. His most recent role has been as Executive Director of Clinical Pharmacology and Quantitative Medicine. He will continue in dual roles as CSO and head of the Quantitative Medicine Program.

As CSO, Dr. Romero will spearhead innovations in research and science by delivering strategic and operational leadership of C-Path’s data-driven nationally and internationally recognized programs in medical product development solutions. In collaboration with senior leadership, he will set the vision for C-Path’s scientific endeavors and ensure that the focus of C-Path’s public-private partnerships stay closely aligned with its mission to accelerate the pace and reduce the costs of medical product development, through innovation in data science, model-informed drug development, patient-centric drug development and precision medicine to optimize the scientific evaluation of the efficacy and safety of new therapies. This will be achieved through strengthening C-Path’s pillars in quantitative medicine, data science, biomarkers, clinical outcome assessment tools and regulatory science.

“With more than 15 years of diverse experience in the drug development space, including demonstrated leadership abilities in heading large programs and cross-functional teams, there are few people who would be equally suited to lead C-Path’s scientific initiatives than Klaus,” said C-Path President and CEO Joseph Scheeren, Pharm. D. “His combination of clinical pharmacology, epidemiology and model and simulation experience, plus his business development expertise and history of fostering meaningful interactions between regulatory agencies, industry, academia and patient groups will be key in enhancing signature C-Path consortia initiatives, while bringing strategic focus to data analytics to drive research and create efficiencies across all stages of drug development.”

C-Path Selects neuroscientist to lead Alzheimer’s Consortium

The Critical Path Institute (C-Path) today announced it has named Sudhir Sivakumaran, Ph.D., as Executive Director of its Critical Path for Alzheimer’s Disease (CPAD) consortium effective immediately. Dr. Sivakumaran, a neuroscientist and research and development professional, has nearly 20 years combined experience in academic, pre-clinical and early clinical research and development, phase 1 and phase 2 clinical study design, data analysis and diligence and business development. He has been with C-Path since July 2019 as Associate Director for CPAD.

As Executive Director of CPAD, Dr. Sivakumaran will guide all operational and scientific input for the CPAD Consortium and develop and implement the strategic plan and priorities for individual working groups within CPAD. He will work with key individuals at global regulatory agencies including the U.S. Food and Drug Administration, European Medicines Agency and the Pharmaceuticals and Medical Devices Agency. Dr. Sivakumaran will also provide scientific leadership and oversee projects dealing with neuroscience, biomarker qualification, clinical outcome assessment development, data sharing and aggregation related to utility of modeling and simulation in Alzheimer’s disease (AD).

“We are thrilled that Sudhir has accepted the role of Executive Director of our long-standing Alzheimer’s consortium, CPAD,” said C-Path President and CEO Joseph Scheeren, Pharm. D. “He brings a wealth of experience to the program and in the short time Sudhir has been with C-Path, he has stepped up to continue to drive CPAD’s initiatives to create new tools and methods to increase the efficiency in the development process of new treatments for AD and related neurodegenerative disorders. With Sudhir leading CPAD, I know we’ll continue to enhance our already ample collaborative efforts with our agency, industry and patient organization partners in this area.”